FDA grants ODD to Candel Therapeutics’ pancreatic cancer treatment

Betsy Goodfellow | April 15, 2024 | News story | Medical Communications Candel Therapeutics, FDA, ODD, Oncology, Pancreatic cancer 

Candel Therapeutics has announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to CAN-2409, Candel’s immunotherapy candidate, for the treatment of pancreatic cancer.

Candel has previously reported updated overall survival data from its ongoing phase 2 clinical trial of CAN-2409 plus valacyclovir, along with standard of care chemoradiation, followed by resection for borderline resectable pancreatic ductal adenocarcinoma (PDAC). This data showed a ‘notable improvement in estimated median overall survival of 28.8 months after experimental treatment with CAN-2409 versus only 12.5 months in the control group’, according to the company’s press release.

Paul Peter Tak MD PhD FMedSci, president and chief executive officer of Candel Therapeutics, commented: “We recently reported data from the phase 2 randomised clinical trial of CAN-2409 in borderline resectable pancreatic cancer, showing that CAN-2409, when added to standard of care, more than doubled the median overall survival obtained with standard of care alone. We are pleased that the FDA has now granted Candel with both Orphan Drug and Fast Track Designation to this programme, as we seek to reshape the treatment paradigm in pancreatic cancer.”

The drug has been generally well tolerated, with no new safety signals being observed throughout the trial, and no dose-limiting toxicities or cases of pancreatitis.

Betsy Goodfellow

Related Content

anirudh-djo3injpaoe-unsplash_3

Pfizer’s Beqvez approved by FDA for haemophilia B treatment

Pfizer has announced that the US Food and Drug Administration (FDA) has approved Beqvez (fidanacogene …

GSK’s Jemperli accepted for FDA review for endometrial cancer treatment

GSK has announced that the US Food and Drug Administration (FDA) has accepted its supplemental …

FDA approves ImmunityBio’s Anktiva bladder cancer treatment

ImmunityBio has announced that the US Food and Drug Administration (FDA) has approved Anktiva (N-803, …

Latest content